Impact of the COVID-19 pandemic in children with allergic asthma
During the pandemic (February-April 2020), the following data were obtained by 2 allergists via telephone interview: family size, presence of SARS-CoV-2 infection (adult cohabitants affected, signs and symptoms, date of onset, treatment, and severity) as well as an asthma-control assessment based on...
Gespeichert in:
| Veröffentlicht in: | The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2020-10, Vol.8 (9), p.3172-3174.e1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3174.e1 |
|---|---|
| container_issue | 9 |
| container_start_page | 3172 |
| container_title | The journal of allergy and clinical immunology in practice (Cambridge, MA) |
| container_volume | 8 |
| creator | Ruano, Francisco Javier Somoza Álvarez, Maria Luisa Haroun-Díaz, Elisa Vázquez de la Torre, María López González, Paula Prieto-Moreno, Ana Torres Rojas, Isabel Cervera García, María Desamparados Pérez Alzate, Diana Blanca-López, Natalia Canto Díez, Gabriela |
| description | During the pandemic (February-April 2020), the following data were obtained by 2 allergists via telephone interview: family size, presence of SARS-CoV-2 infection (adult cohabitants affected, signs and symptoms, date of onset, treatment, and severity) as well as an asthma-control assessment based on a validated Spanish child asthma-control questionnaire6 and asthma-control measures required in the previous 4 weeks. [...]during the phone call, parents did not report worsening of symptoms compared with the same period in the previous year. Asthma severity and control were not associated with a worse clinical course, so we can conclude that allergic asthmatic children are not more vulnerable to suffer from COVID-19.Online Repository Epidemiological features Age (y), median (IQR) 10 (7-11) Gender M/T 63% Family atopy 76% Allergic comorbidities Rhinitis 90% Conjunctivitis 85% Atopic dermatitis 50% Food allergy 36% Sensitization to aeroallergens Pollen 90% Animal dander 49% Molds 23% House dust mite 19% Type of allergic asthma Seasonal 49% Perennial 51% Asthma treatment∗ Step 1 40% Step 2 21% Steps 3 and 4 35% Step 5 4% Table I Total cases (n = 212): description of epidemiological and allergic features Probable COVID-19 cases 29 (14%) Non-COVID-19 cases 183 (86%) Statistical differences Epidemiological features Age (y), median (IQR) 10 (7-11) 10 (7-11) P = .72 Gender M/T 79% 61% P = .06 Family atopy 83% 75% P = .35 Allergic comorbidities Rhinitis 83% 91% P = .19 Conjunctivitis 76% 87% P = .12 Atopic dermatitis 62% 47% P = .15 Food allergy 59% 33% P = .007 Asthma treatment∗ Step 1 45% 39% P = .537 Step 2 31% 20% P = .585 Steps 3 and 4 24% 37% P = .487 Step 5 0% 4% P = .378 Lung function† FVC, FEV1, and FEV1/FVC ≥ 80% 72% 75% P = .682 Asthma control‡ OCS 10% 17% P = .328 Emergency care 27% 22% P = .652 Hospital admission 3% 6% P = .505 COVID-19 period (February-April 2020) Asthma control questionnaire CAN < 8§ 93% 97% P = .301 Rhinoconjunctivitis 38% 42% P = .714 Increase in reliever treatment (SABA) 34% 8% P < .001 Increase in asthma controller treatment 14% 3% P < .01 Table II Comparison between COVID-19 and non-COVID-19 allergic asthmatic children |
| doi_str_mv | 10.1016/j.jaip.2020.07.019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7384405</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213219820307273</els_id><sourcerecordid>2448837658</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-d0f21f1ba545197ca4c8774150f41d13a4a3b0c3879a208f08a979aa468af9563</originalsourceid><addsrcrecordid>eNp9kU1LJDEQhoMoKuof8CANXrx0b-WjJ2kQcZld3QHBi3oNNem0naa_THpc_PdmGBX1YC4pqKdeUnkIOaaQUaCzX03WoBszBgwykBnQYovsM0Z5yhjQ7feaFmqPHIXQQDyKShCwS_Y4kxwUF_vkctGNaKZkqJKptsn89mHxJ6VFMmJf2s6ZxPWJqV1betsn_91UJ9i21j_GDoap7vCQ7FTYBnv0dh-Q-6u_d_N_6c3t9WL--yY1QvEpLaFitKJLzEVOC2lQGCWloDlUgpaUo0C-BMOVLJCBqkBhEUsUM4VVkc_4AbnY5I6rZWdLY_vJY6tH7zr0L3pAp792elfrx-FZS66EgDwGnL0F-OFpZcOkOxeMbVvs7bAKmglWSAVcQkRPv6HNsPJ9XC9SQikuZ7mKFNtQxg8heFt9PIaCXjvSjV470mtHGqSOjuLQyec1PkbejUTgfAPY-JnPznodjLO9saXz1ky6HNxP-a_uF6AF</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2448837658</pqid></control><display><type>article</type><title>Impact of the COVID-19 pandemic in children with allergic asthma</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ruano, Francisco Javier ; Somoza Álvarez, Maria Luisa ; Haroun-Díaz, Elisa ; Vázquez de la Torre, María ; López González, Paula ; Prieto-Moreno, Ana ; Torres Rojas, Isabel ; Cervera García, María Desamparados ; Pérez Alzate, Diana ; Blanca-López, Natalia ; Canto Díez, Gabriela</creator><creatorcontrib>Ruano, Francisco Javier ; Somoza Álvarez, Maria Luisa ; Haroun-Díaz, Elisa ; Vázquez de la Torre, María ; López González, Paula ; Prieto-Moreno, Ana ; Torres Rojas, Isabel ; Cervera García, María Desamparados ; Pérez Alzate, Diana ; Blanca-López, Natalia ; Canto Díez, Gabriela</creatorcontrib><description>During the pandemic (February-April 2020), the following data were obtained by 2 allergists via telephone interview: family size, presence of SARS-CoV-2 infection (adult cohabitants affected, signs and symptoms, date of onset, treatment, and severity) as well as an asthma-control assessment based on a validated Spanish child asthma-control questionnaire6 and asthma-control measures required in the previous 4 weeks. [...]during the phone call, parents did not report worsening of symptoms compared with the same period in the previous year. Asthma severity and control were not associated with a worse clinical course, so we can conclude that allergic asthmatic children are not more vulnerable to suffer from COVID-19.Online Repository Epidemiological features Age (y), median (IQR) 10 (7-11) Gender M/T 63% Family atopy 76% Allergic comorbidities Rhinitis 90% Conjunctivitis 85% Atopic dermatitis 50% Food allergy 36% Sensitization to aeroallergens Pollen 90% Animal dander 49% Molds 23% House dust mite 19% Type of allergic asthma Seasonal 49% Perennial 51% Asthma treatment∗ Step 1 40% Step 2 21% Steps 3 and 4 35% Step 5 4% Table I Total cases (n = 212): description of epidemiological and allergic features Probable COVID-19 cases 29 (14%) Non-COVID-19 cases 183 (86%) Statistical differences Epidemiological features Age (y), median (IQR) 10 (7-11) 10 (7-11) P = .72 Gender M/T 79% 61% P = .06 Family atopy 83% 75% P = .35 Allergic comorbidities Rhinitis 83% 91% P = .19 Conjunctivitis 76% 87% P = .12 Atopic dermatitis 62% 47% P = .15 Food allergy 59% 33% P = .007 Asthma treatment∗ Step 1 45% 39% P = .537 Step 2 31% 20% P = .585 Steps 3 and 4 24% 37% P = .487 Step 5 0% 4% P = .378 Lung function† FVC, FEV1, and FEV1/FVC ≥ 80% 72% 75% P = .682 Asthma control‡ OCS 10% 17% P = .328 Emergency care 27% 22% P = .652 Hospital admission 3% 6% P = .505 COVID-19 period (February-April 2020) Asthma control questionnaire CAN < 8§ 93% 97% P = .301 Rhinoconjunctivitis 38% 42% P = .714 Increase in reliever treatment (SABA) 34% 8% P < .001 Increase in asthma controller treatment 14% 3% P < .01 Table II Comparison between COVID-19 and non-COVID-19 allergic asthmatic children</description><identifier>ISSN: 2213-2198</identifier><identifier>EISSN: 2213-2201</identifier><identifier>DOI: 10.1016/j.jaip.2020.07.019</identifier><identifier>PMID: 32730834</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acetaminophen - therapeutic use ; Adolescent ; Adrenal Cortex Hormones - therapeutic use ; Adrenergic beta-2 Receptor Agonists - therapeutic use ; Age ; Allergens ; Analgesics, Non-Narcotic - therapeutic use ; Anti-Asthmatic Agents - therapeutic use ; Asthma ; Asthma - drug therapy ; Asthma - epidemiology ; Atopic dermatitis ; Betacoronavirus ; Child ; Child, Preschool ; Children ; Children & youth ; Clinical Communications ; Conjunctivitis ; Coronavirus Infections - diagnosis ; Coronavirus Infections - drug therapy ; Coronavirus Infections - epidemiology ; Coronaviruses ; COVID-19 ; Dander ; Dermatitis ; Eczema ; Emergency medical care ; Epidemiology ; Families & family life ; Family medical history ; Female ; Food allergies ; Gender ; Humans ; Infections ; Inhalers ; Male ; Pandemics ; Pneumonia, Viral - diagnosis ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - epidemiology ; Respiratory function ; Rhinitis ; Rhinoconjunctivitis ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Spain - epidemiology ; Spirometry</subject><ispartof>The journal of allergy and clinical immunology in practice (Cambridge, MA), 2020-10, Vol.8 (9), p.3172-3174.e1</ispartof><rights>2020 American Academy of Allergy, Asthma & Immunology</rights><rights>2020. American Academy of Allergy, Asthma & Immunology</rights><rights>2020 American Academy of Allergy, Asthma & Immunology. 2020 American Academy of Allergy, Asthma & Immunology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-d0f21f1ba545197ca4c8774150f41d13a4a3b0c3879a208f08a979aa468af9563</citedby><cites>FETCH-LOGICAL-c483t-d0f21f1ba545197ca4c8774150f41d13a4a3b0c3879a208f08a979aa468af9563</cites><orcidid>0000-0003-4098-3446</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32730834$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ruano, Francisco Javier</creatorcontrib><creatorcontrib>Somoza Álvarez, Maria Luisa</creatorcontrib><creatorcontrib>Haroun-Díaz, Elisa</creatorcontrib><creatorcontrib>Vázquez de la Torre, María</creatorcontrib><creatorcontrib>López González, Paula</creatorcontrib><creatorcontrib>Prieto-Moreno, Ana</creatorcontrib><creatorcontrib>Torres Rojas, Isabel</creatorcontrib><creatorcontrib>Cervera García, María Desamparados</creatorcontrib><creatorcontrib>Pérez Alzate, Diana</creatorcontrib><creatorcontrib>Blanca-López, Natalia</creatorcontrib><creatorcontrib>Canto Díez, Gabriela</creatorcontrib><title>Impact of the COVID-19 pandemic in children with allergic asthma</title><title>The journal of allergy and clinical immunology in practice (Cambridge, MA)</title><addtitle>J Allergy Clin Immunol Pract</addtitle><description>During the pandemic (February-April 2020), the following data were obtained by 2 allergists via telephone interview: family size, presence of SARS-CoV-2 infection (adult cohabitants affected, signs and symptoms, date of onset, treatment, and severity) as well as an asthma-control assessment based on a validated Spanish child asthma-control questionnaire6 and asthma-control measures required in the previous 4 weeks. [...]during the phone call, parents did not report worsening of symptoms compared with the same period in the previous year. Asthma severity and control were not associated with a worse clinical course, so we can conclude that allergic asthmatic children are not more vulnerable to suffer from COVID-19.Online Repository Epidemiological features Age (y), median (IQR) 10 (7-11) Gender M/T 63% Family atopy 76% Allergic comorbidities Rhinitis 90% Conjunctivitis 85% Atopic dermatitis 50% Food allergy 36% Sensitization to aeroallergens Pollen 90% Animal dander 49% Molds 23% House dust mite 19% Type of allergic asthma Seasonal 49% Perennial 51% Asthma treatment∗ Step 1 40% Step 2 21% Steps 3 and 4 35% Step 5 4% Table I Total cases (n = 212): description of epidemiological and allergic features Probable COVID-19 cases 29 (14%) Non-COVID-19 cases 183 (86%) Statistical differences Epidemiological features Age (y), median (IQR) 10 (7-11) 10 (7-11) P = .72 Gender M/T 79% 61% P = .06 Family atopy 83% 75% P = .35 Allergic comorbidities Rhinitis 83% 91% P = .19 Conjunctivitis 76% 87% P = .12 Atopic dermatitis 62% 47% P = .15 Food allergy 59% 33% P = .007 Asthma treatment∗ Step 1 45% 39% P = .537 Step 2 31% 20% P = .585 Steps 3 and 4 24% 37% P = .487 Step 5 0% 4% P = .378 Lung function† FVC, FEV1, and FEV1/FVC ≥ 80% 72% 75% P = .682 Asthma control‡ OCS 10% 17% P = .328 Emergency care 27% 22% P = .652 Hospital admission 3% 6% P = .505 COVID-19 period (February-April 2020) Asthma control questionnaire CAN < 8§ 93% 97% P = .301 Rhinoconjunctivitis 38% 42% P = .714 Increase in reliever treatment (SABA) 34% 8% P < .001 Increase in asthma controller treatment 14% 3% P < .01 Table II Comparison between COVID-19 and non-COVID-19 allergic asthmatic children</description><subject>Acetaminophen - therapeutic use</subject><subject>Adolescent</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adrenergic beta-2 Receptor Agonists - therapeutic use</subject><subject>Age</subject><subject>Allergens</subject><subject>Analgesics, Non-Narcotic - therapeutic use</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Asthma - epidemiology</subject><subject>Atopic dermatitis</subject><subject>Betacoronavirus</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Children & youth</subject><subject>Clinical Communications</subject><subject>Conjunctivitis</subject><subject>Coronavirus Infections - diagnosis</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Dander</subject><subject>Dermatitis</subject><subject>Eczema</subject><subject>Emergency medical care</subject><subject>Epidemiology</subject><subject>Families & family life</subject><subject>Family medical history</subject><subject>Female</subject><subject>Food allergies</subject><subject>Gender</subject><subject>Humans</subject><subject>Infections</subject><subject>Inhalers</subject><subject>Male</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - diagnosis</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Respiratory function</subject><subject>Rhinitis</subject><subject>Rhinoconjunctivitis</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spain - epidemiology</subject><subject>Spirometry</subject><issn>2213-2198</issn><issn>2213-2201</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1LJDEQhoMoKuof8CANXrx0b-WjJ2kQcZld3QHBi3oNNem0naa_THpc_PdmGBX1YC4pqKdeUnkIOaaQUaCzX03WoBszBgwykBnQYovsM0Z5yhjQ7feaFmqPHIXQQDyKShCwS_Y4kxwUF_vkctGNaKZkqJKptsn89mHxJ6VFMmJf2s6ZxPWJqV1betsn_91UJ9i21j_GDoap7vCQ7FTYBnv0dh-Q-6u_d_N_6c3t9WL--yY1QvEpLaFitKJLzEVOC2lQGCWloDlUgpaUo0C-BMOVLJCBqkBhEUsUM4VVkc_4AbnY5I6rZWdLY_vJY6tH7zr0L3pAp792elfrx-FZS66EgDwGnL0F-OFpZcOkOxeMbVvs7bAKmglWSAVcQkRPv6HNsPJ9XC9SQikuZ7mKFNtQxg8heFt9PIaCXjvSjV470mtHGqSOjuLQyec1PkbejUTgfAPY-JnPznodjLO9saXz1ky6HNxP-a_uF6AF</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Ruano, Francisco Javier</creator><creator>Somoza Álvarez, Maria Luisa</creator><creator>Haroun-Díaz, Elisa</creator><creator>Vázquez de la Torre, María</creator><creator>López González, Paula</creator><creator>Prieto-Moreno, Ana</creator><creator>Torres Rojas, Isabel</creator><creator>Cervera García, María Desamparados</creator><creator>Pérez Alzate, Diana</creator><creator>Blanca-López, Natalia</creator><creator>Canto Díez, Gabriela</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><general>American Academy of Allergy, Asthma & Immunology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4098-3446</orcidid></search><sort><creationdate>20201001</creationdate><title>Impact of the COVID-19 pandemic in children with allergic asthma</title><author>Ruano, Francisco Javier ; Somoza Álvarez, Maria Luisa ; Haroun-Díaz, Elisa ; Vázquez de la Torre, María ; López González, Paula ; Prieto-Moreno, Ana ; Torres Rojas, Isabel ; Cervera García, María Desamparados ; Pérez Alzate, Diana ; Blanca-López, Natalia ; Canto Díez, Gabriela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-d0f21f1ba545197ca4c8774150f41d13a4a3b0c3879a208f08a979aa468af9563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acetaminophen - therapeutic use</topic><topic>Adolescent</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adrenergic beta-2 Receptor Agonists - therapeutic use</topic><topic>Age</topic><topic>Allergens</topic><topic>Analgesics, Non-Narcotic - therapeutic use</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Asthma - epidemiology</topic><topic>Atopic dermatitis</topic><topic>Betacoronavirus</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Children & youth</topic><topic>Clinical Communications</topic><topic>Conjunctivitis</topic><topic>Coronavirus Infections - diagnosis</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Dander</topic><topic>Dermatitis</topic><topic>Eczema</topic><topic>Emergency medical care</topic><topic>Epidemiology</topic><topic>Families & family life</topic><topic>Family medical history</topic><topic>Female</topic><topic>Food allergies</topic><topic>Gender</topic><topic>Humans</topic><topic>Infections</topic><topic>Inhalers</topic><topic>Male</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - diagnosis</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Respiratory function</topic><topic>Rhinitis</topic><topic>Rhinoconjunctivitis</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spain - epidemiology</topic><topic>Spirometry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ruano, Francisco Javier</creatorcontrib><creatorcontrib>Somoza Álvarez, Maria Luisa</creatorcontrib><creatorcontrib>Haroun-Díaz, Elisa</creatorcontrib><creatorcontrib>Vázquez de la Torre, María</creatorcontrib><creatorcontrib>López González, Paula</creatorcontrib><creatorcontrib>Prieto-Moreno, Ana</creatorcontrib><creatorcontrib>Torres Rojas, Isabel</creatorcontrib><creatorcontrib>Cervera García, María Desamparados</creatorcontrib><creatorcontrib>Pérez Alzate, Diana</creatorcontrib><creatorcontrib>Blanca-López, Natalia</creatorcontrib><creatorcontrib>Canto Díez, Gabriela</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ruano, Francisco Javier</au><au>Somoza Álvarez, Maria Luisa</au><au>Haroun-Díaz, Elisa</au><au>Vázquez de la Torre, María</au><au>López González, Paula</au><au>Prieto-Moreno, Ana</au><au>Torres Rojas, Isabel</au><au>Cervera García, María Desamparados</au><au>Pérez Alzate, Diana</au><au>Blanca-López, Natalia</au><au>Canto Díez, Gabriela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of the COVID-19 pandemic in children with allergic asthma</atitle><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle><addtitle>J Allergy Clin Immunol Pract</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>8</volume><issue>9</issue><spage>3172</spage><epage>3174.e1</epage><pages>3172-3174.e1</pages><issn>2213-2198</issn><eissn>2213-2201</eissn><abstract>During the pandemic (February-April 2020), the following data were obtained by 2 allergists via telephone interview: family size, presence of SARS-CoV-2 infection (adult cohabitants affected, signs and symptoms, date of onset, treatment, and severity) as well as an asthma-control assessment based on a validated Spanish child asthma-control questionnaire6 and asthma-control measures required in the previous 4 weeks. [...]during the phone call, parents did not report worsening of symptoms compared with the same period in the previous year. Asthma severity and control were not associated with a worse clinical course, so we can conclude that allergic asthmatic children are not more vulnerable to suffer from COVID-19.Online Repository Epidemiological features Age (y), median (IQR) 10 (7-11) Gender M/T 63% Family atopy 76% Allergic comorbidities Rhinitis 90% Conjunctivitis 85% Atopic dermatitis 50% Food allergy 36% Sensitization to aeroallergens Pollen 90% Animal dander 49% Molds 23% House dust mite 19% Type of allergic asthma Seasonal 49% Perennial 51% Asthma treatment∗ Step 1 40% Step 2 21% Steps 3 and 4 35% Step 5 4% Table I Total cases (n = 212): description of epidemiological and allergic features Probable COVID-19 cases 29 (14%) Non-COVID-19 cases 183 (86%) Statistical differences Epidemiological features Age (y), median (IQR) 10 (7-11) 10 (7-11) P = .72 Gender M/T 79% 61% P = .06 Family atopy 83% 75% P = .35 Allergic comorbidities Rhinitis 83% 91% P = .19 Conjunctivitis 76% 87% P = .12 Atopic dermatitis 62% 47% P = .15 Food allergy 59% 33% P = .007 Asthma treatment∗ Step 1 45% 39% P = .537 Step 2 31% 20% P = .585 Steps 3 and 4 24% 37% P = .487 Step 5 0% 4% P = .378 Lung function† FVC, FEV1, and FEV1/FVC ≥ 80% 72% 75% P = .682 Asthma control‡ OCS 10% 17% P = .328 Emergency care 27% 22% P = .652 Hospital admission 3% 6% P = .505 COVID-19 period (February-April 2020) Asthma control questionnaire CAN < 8§ 93% 97% P = .301 Rhinoconjunctivitis 38% 42% P = .714 Increase in reliever treatment (SABA) 34% 8% P < .001 Increase in asthma controller treatment 14% 3% P < .01 Table II Comparison between COVID-19 and non-COVID-19 allergic asthmatic children</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32730834</pmid><doi>10.1016/j.jaip.2020.07.019</doi><orcidid>https://orcid.org/0000-0003-4098-3446</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2213-2198 |
| ispartof | The journal of allergy and clinical immunology in practice (Cambridge, MA), 2020-10, Vol.8 (9), p.3172-3174.e1 |
| issn | 2213-2198 2213-2201 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7384405 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Acetaminophen - therapeutic use Adolescent Adrenal Cortex Hormones - therapeutic use Adrenergic beta-2 Receptor Agonists - therapeutic use Age Allergens Analgesics, Non-Narcotic - therapeutic use Anti-Asthmatic Agents - therapeutic use Asthma Asthma - drug therapy Asthma - epidemiology Atopic dermatitis Betacoronavirus Child Child, Preschool Children Children & youth Clinical Communications Conjunctivitis Coronavirus Infections - diagnosis Coronavirus Infections - drug therapy Coronavirus Infections - epidemiology Coronaviruses COVID-19 Dander Dermatitis Eczema Emergency medical care Epidemiology Families & family life Family medical history Female Food allergies Gender Humans Infections Inhalers Male Pandemics Pneumonia, Viral - diagnosis Pneumonia, Viral - drug therapy Pneumonia, Viral - epidemiology Respiratory function Rhinitis Rhinoconjunctivitis SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Spain - epidemiology Spirometry |
| title | Impact of the COVID-19 pandemic in children with allergic asthma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A44%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20the%20COVID-19%20pandemic%20in%20children%20with%20allergic%20asthma&rft.jtitle=The%20journal%20of%20allergy%20and%20clinical%20immunology%20in%20practice%20(Cambridge,%20MA)&rft.au=Ruano,%20Francisco%20Javier&rft.date=2020-10-01&rft.volume=8&rft.issue=9&rft.spage=3172&rft.epage=3174.e1&rft.pages=3172-3174.e1&rft.issn=2213-2198&rft.eissn=2213-2201&rft_id=info:doi/10.1016/j.jaip.2020.07.019&rft_dat=%3Cproquest_pubme%3E2448837658%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2448837658&rft_id=info:pmid/32730834&rft_els_id=S2213219820307273&rfr_iscdi=true |